Rare Gene Variant Offers 60% Risk Reduction for Diabetes and Heart Disease

Study of 1 million people identifies protective genetic variant that could enable cheaper treatments for cardiometabolic diseases

A global study of over 1 million individuals across three continents identified a rare protective variant in the FNIP1 gene. This variant occurs in about 1 in 7,000 people and correlates with a 60% reduced risk of cardiometabolic disease. The variant shows biological effects in human liver cells and mice: silencing FNIP1 increases fat breakdown pathways, reduces liver fat, improves insulin sensitivity, and stabilizes blood glucose in high-fat diets. It also links to improved triglyceride-to-HDL ratios, lower insulin levels, reduced blood pressure, and less fat accumulation in liver and muscle tissues.

The mechanism suggests targeting FNIP1 via gene editing could replicate these protective effects. However, the study confirms the variant only provides benefits when inherited from birth—later interventions would likely not replicate the developmental effects observed. Therapeutic applications face significant hurdles: systemic FNIP1 disruption risks liver damage or cancer, and precise liver-specific delivery (like lipid nanoparticles) is required to avoid side effects.

This finding moves abundance toward more accessible diabetes and heart disease management for those with the variant. By enabling targeted treatments that avoid broad pharmaceutical costs, it could reduce long-term health expenses for millions. But the variant’s rarity and the need for precise delivery mean its impact remains limited to specific populations. What follows will be whether liver-focused gene therapies can safely replicate these effects without triggering new health risks.

*Source limitation: The study used population-level biomarkers rather than direct clinical outcomes in humans.*

Source: Singularity Hub